目的：探讨肾癌患者保留肾单位手术后应用索拉非尼对预防癌细胞转移的价值。方法：选取2008年2月至2014年3月在我院行保留肾单位手术治疗，且术后存在复发转移高危因素的肾癌患者68例，其中26例患者术后给予索拉非尼口服治疗（观察组），42例患者术后给予生物化疗治疗（对照组）。术后随访，比较两组患者术后复发转移及生存情况。结果：观察组患者中位生存时间为21.40个月，对照组为18.83个月（P＜0.05）；观察组患者术后中位复发或转移时间及复发或转移后生存时间分别为16.17个月和15.80个月，对照组为14.43个月和13.67个月（P＜0.05）；两组患者不良反应发生情况比较，差异无统计学意义（P＞0.05）。结论：保留肾单位手术后应用索拉非尼治疗可延长肾癌患者术后复发转移时间及复发转移后生存时间，长期使用不良反应轻微，患者可耐受，值得临床推广。%Objective: To analyze the value of application of sorafinib in the patients with renal carcinoma after nephron-sparing surgery for the prevention of recurrence and metastasis.Methods: Sixty-eight cases of patients with renal carcinoma treated by nephron-sparing surgery in our hospital from February, 2008 to March, 2014 with risk factors of recurrence and metastasis were selected, in which 26 cases of patients treated by oral soraifnib and 42 cases of patients treated by biological therapy and chemotherapy were divided into an observational group and a control group. The recurrence, metastasis and survival were compared between two groups after postoperative follow-up.Results:The median survival time was 21.40 months in the observational group and 18.38 months in the control group (P 0.05).Conclusion: Soraifnib applied after nephron-sparing surgery can extend the times for recurrence and metastasis and the survival and the adverse reactions were mild and can be tolerated by patients, so it is worthy of promotion.
展开▼
